Leonard Joseph Appleman MD
Genitourinary Oncology
Associate Professor, Medicine, University of Pittsburgh School of Medicine
Join to View Full Profile
5115 Centre AvePittsburgh, PA 15232
Phone+1 412-692-4724
Fax+1 412-692-4905
Dr. Appleman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1995 - 1998
New York University School of MedicineClass of 1995
Certifications & Licensure
PA State Medical License 2006 - 2026
MA State Medical License 1998 - 2006
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- A Study of Imatinib and Docetaxel in Prostate Cancer Start of enrollment: 2005 Aug 01
- Study of Oxaliplatin and Taxotere in Prostate Cancer Start of enrollment: 2004 Nov 01
- MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer Start of enrollment: 2006 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Kelly J Wilkinson, Emily M Whitman-Purves
Clinical Cancer Research. 2024-12-16 - 1 citationsPembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Coh...Evan Y Yu, Cristiano Ferrario, Mark D Linch, Michael Stoeckle, Brigitte Laguerre
European Urology Oncology. 2024-06-25 - 3 citationsRandomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasect...Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins
Journal of Clinical Oncology. 2024-06-10
Lectures
- Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metasta...2019 ASCO Annual Meeting - 6/1/2019
- Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
The Society for Immunotherapy of Cancer (SITC) Invites You to Attend the Virtual Press Briefing of the Society’s 36th Anniversary Annual MeetingNovember 2nd, 2021
Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCCJune 14th, 2019
No Benefit from Pazopanib in Advanced Kidney Cancer After Surgery to Remove MetastasesJune 3rd, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
